Compare Amplify Transformational Data Sharing ETF (BLOK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.06, while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | VRTX | |
|---|---|---|
52-Week High | $74.10 | $529.65 |
52-Week Low | $47.36 | $376.62 |
Market Cap | — | $132.79B |
Sector | — | Health |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $59.89 with minimal daily movement (+0.4%). Technical indicators show a bearish trend with all 13 moving averages signaling sell, while oscillators remain neutral. The stock faces resistance at $60 and support at $59. Recent news highlights the ETF's diversified blockchain economy exposure and inclusion of SpaceX shares following its historic IPO.
The outlook remains cautious due to strong bearish technical signals and sector volatility. Investment opportunity lies in diversified blockchain economy exposure, but risks include market sentiment shifts and competitive ETF landscape. Wall Street sentiment appears mixed with technical weakness offset by strategic positioning in growing sectors.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
